These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30707355)

  • 1. Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank.
    Norring-Agerskov D; Bathum L; Pedersen OB; Abrahamsen B; Lauritzen JB; Jørgensen NR; Jørgensen HL
    Aging Clin Exp Res; 2019 Dec; 31(12):1727-1734. PubMed ID: 30707355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
    Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
    World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture.
    Norring-Agerskov D; Madsen CM; Bathum L; Pedersen OB; Lauritzen JB; Jørgensen NR; Jørgensen HL
    Osteoporos Int; 2019 Sep; 30(9):1767-1778. PubMed ID: 31278472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients.
    Rapacki E; Lauritzen JB; Madsen CM; Jørgensen HL; Norring-Agerskov D
    Eur J Trauma Emerg Surg; 2021 Aug; 47(4):1081-1087. PubMed ID: 31696265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
    Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
    Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.
    Meyer J; Alstrup M; Rasmussen LJH; Schultz M; Ladelund S; Haupt TH; Tingleff J; Iversen K; Eugen-Olsen J
    Scand J Trauma Resusc Emerg Med; 2018 Feb; 26(1):11. PubMed ID: 29391054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Markers and the Risk of Hip and Vertebral Fractures in Men: the Osteoporotic Fractures in Men (MrOS).
    Cauley JA; Barbour KE; Harrison SL; Cloonan YK; Danielson ME; Ensrud KE; Fink HA; Orwoll ES; Boudreau R
    J Bone Miner Res; 2016 Dec; 31(12):2129-2138. PubMed ID: 27371811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.
    Rasmussen LJH; Ladelund S; Haupt TH; Ellekilde GE; Eugen-Olsen J; Andersen O
    Crit Care Med; 2018 Dec; 46(12):1961-1968. PubMed ID: 30247244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
    Hodges GW; Bang CN; Forman JL; Olsen MH; Boman K; Ray S; Kesäniemi YA; Eugen-Olsen J; Greve AM; Jeppesen JL; Wachtell K
    Atherosclerosis; 2018 May; 272():129-136. PubMed ID: 29602140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
    Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
    Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.
    Nayak RK; Allingstrup M; Phanareth K; Kofoed-Enevoldsen A
    Dan Med J; 2015 Oct; 62(10):A5146. PubMed ID: 26441392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated ferritin and circulating osteoprotegerin levels as independent predictors of hip fracture in postmenopausal women admitted for fragility fracture: time for new screening strategies?
    Lipovetzki Y; Zandman-Goddard G; Feldbrin Z; Shargorodsky M
    Immunol Res; 2017 Feb; 65(1):423-427. PubMed ID: 27503623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.